• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Altria Group, Inc. Announces Retirement of CEO Billy Gifford and Appointment of Sal Mancuso as Successor

    12/11/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MO alert in real time by email

    Altria Group, Inc. (Altria) (NYSE:MO) announces today that Billy Gifford, Altria's Chief Executive Officer (CEO), has decided to retire, effective May 14, 2026 at the conclusion of the 2026 Annual Meeting of Shareholders (2026 Annual Meeting). Billy has had a distinguished career of over 30 years with the Altria family of companies and has served as Altria's CEO since 2020. Altria's Board of Directors (Board) has elected Salvatore (Sal) Mancuso to serve as Altria's CEO upon Billy's retirement. To facilitate a smooth transition, Billy plans to serve as a consultant to Altria upon his retirement through at least the end of 2026. Additionally, the Board elected Heather Newman to serve as Altria's Chief Financial Officer (CFO) effective May 14, 2026, at the conclusion of the 2026 Annual Meeting.

    Sal joined Philip Morris USA (PM USA) in 1990 and has served in numerous leadership positions during his career at the Altria family of companies, including as Altria's Executive Vice President and CFO since 2020 and in various other roles in our strategy, finance and compliance organizations. He also currently serves on the board of directors of Anheuser-Busch InBev (ABI) as an Altria designee.

    "We believe Sal has deep industry knowledge, a keen understanding of Altria's challenges and opportunities, and a commitment to our 2028 Enterprise Goals," said Board Chair Kathryn McQuade. "Our election of Sal as the next CEO is a result of our ongoing, long-term succession planning process, which included rigorous third-party assessments of multiple internal candidates and an evaluation of external talent in the consumer packaged goods industry. We believe Sal has transformational leadership skills and a results-driven mindset, coupled with the passion and grit to execute and deliver Altria's Vision."

    "The Board is immensely grateful for Billy's extraordinary leadership and career at the Altria family of companies," said Ms. McQuade. "We respect his decision to focus on pursuing personal passions and congratulate him on a well-earned retirement. Billy became CEO at a turbulent and difficult time for our company. Under Billy's steady leadership, Altria has been able to address and navigate various challenges while focusing on our Vision and organization, maintaining the strength of our core businesses and delivering strong financial returns to our shareholders. His collaborative leadership style built a stronger leadership team and organization that we believe will continue to forge our path forward in Moving Beyond Smoking®."

    "I've been honored and grateful to lead this amazing company alongside so many talented colleagues across the organization," said Billy. "I'm proud of the progress we've made over the past five years and will retire knowing the company is in good hands. I look forward to my next chapter, spending more time with my growing family and giving back to my community. I appreciate the Board's support of my decision and have great confidence in Sal's ability to lead the company going forward. He is driven, is committed to Altria's strategy, and values our fantastic employees. Altria has a bright future under his leadership."

    "I'm humbled and honored to be elected Altria's next CEO," said Sal. "I thank Billy for his leadership of our great company. Billy and I have worked together for many years, and I'm committed to building upon the transformation he started and accelerating progress toward our Vision. We're Moving Beyond Smoking®, and I'm extremely excited about our future and leading the incredible talent who will take us there."

    Heather's election as CFO is also the result of the Board's succession planning process. Heather joined the Altria family of companies in 1999 and has served as Altria's Chief Strategy and Growth Officer since March 2022. Heather currently oversees corporate strategy and development, international and new growth ventures, and our digital and transformation organization. She previously served in numerous leadership positions, including President and CEO, PM USA. "Heather is a highly respected, strategic and collaborative leader. I look forward to working closely with her as our next CFO," said Sal.

    Altria's Profile

    We have a leading portfolio of tobacco products for U.S. tobacco consumers age 21+. We are Moving Beyond Smoking®, by responsibly: transitioning adult smokers to a smoke-free future; competing vigorously for existing smoke-free adult nicotine consumers; and exploring new growth opportunities — beyond the United States and beyond nicotine (Vision). To achieve our Vision, we will pursue initiatives designed to promote the long-term welfare of our company, our stakeholders, society at large and the environment.

    Our wholly owned subsidiaries include leading manufacturers of both combustible and smoke-free products. In combustibles, we own PM USA, the most profitable U.S. cigarette manufacturer, and John Middleton Co. (Middleton), a leading U.S. cigar manufacturer. Our smoke-free portfolio includes ownership of U.S. Smokeless Tobacco Company LLC (USSTC), the leading global moist smokeless tobacco (MST) manufacturer, Helix Innovations LLC (Helix), a leading manufacturer of oral nicotine pouches, and NJOY, LLC (NJOY), an e-vapor manufacturer with products covered by marketing granted orders from the U.S. Food and Drug Administration (FDA). Additionally, we have a majority-owned joint venture, Horizon Innovations LLC (Horizon), for the U.S. marketing and commercialization of heated tobacco stick products.

    Our equity investments include ABI, the world's largest brewer, and Cronos Group Inc. (Cronos), a leading Canadian cannabinoid company.

    The brand portfolios of our operating companies include Marlboro®, Black & Mild®, Copenhagen®, Skoal®, on!® and NJOY®. Trademarks related to Altria referenced in this release are the property of Altria or our subsidiaries or are used with permission.

    Learn more about Altria at www.altria.com and follow us on X, Facebook and LinkedIn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251210481760/en/

    Investor Relations

    Altria Client Services

    (804) 484-8222

    Media Relations

    Altria Client Services

    (804) 484-8897

    www.altria.com/contact-us/media

    Get the next $MO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MO

    DatePrice TargetRatingAnalyst
    7/9/2025$50.00Underperform
    Jefferies
    7/2/2025$59.00Sell → Neutral
    UBS
    4/1/2025Buy → Hold
    Deutsche Bank
    1/16/2025$54.00Equal-Weight
    Morgan Stanley
    12/6/2024$55.00 → $65.00Neutral → Buy
    BofA Securities
    10/8/2024$44.50 → $48.00Neutral
    Citigroup
    1/23/2024Sell
    UBS
    4/14/2023$52.00Buy
    Stifel
    More analyst ratings

    $MO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Ch.Strategy & Growth Off Newman Heather A. covered exercise/tax liability with 10,331 shares, decreasing direct ownership by 8% to 120,667 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    8/25/25 2:41:49 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SVP, Chief HR Off. & CCO Whitaker Charles N. covered exercise/tax liability with 10,331 shares, decreasing direct ownership by 6% to 177,296 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    8/25/25 2:41:27 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    EVP & CFO Mancuso Salvatore covered exercise/tax liability with 15,496 shares, decreasing direct ownership by 6% to 255,118 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    8/25/25 2:40:36 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    SEC Filings

    View All

    Altria Group Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ALTRIA GROUP, INC. (0000764180) (Filer)

    12/11/25 7:06:54 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Altria Group Inc.

    10-Q - ALTRIA GROUP, INC. (0000764180) (Filer)

    10/30/25 7:21:52 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - ALTRIA GROUP, INC. (0000764180) (Filer)

    10/30/25 7:03:10 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Altria with a new price target

    Jefferies resumed coverage of Altria with a rating of Underperform and set a new price target of $50.00

    7/9/25 8:26:04 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria upgraded by UBS with a new price target

    UBS upgraded Altria from Sell to Neutral and set a new price target of $59.00

    7/2/25 7:43:20 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria downgraded by Deutsche Bank

    Deutsche Bank downgraded Altria from Buy to Hold

    4/1/25 3:04:54 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Altria Group, Inc. Announces Retirement of CEO Billy Gifford and Appointment of Sal Mancuso as Successor

    Altria Group, Inc. (Altria) (NYSE:MO) announces today that Billy Gifford, Altria's Chief Executive Officer (CEO), has decided to retire, effective May 14, 2026 at the conclusion of the 2026 Annual Meeting of Shareholders (2026 Annual Meeting). Billy has had a distinguished career of over 30 years with the Altria family of companies and has served as Altria's CEO since 2020. Altria's Board of Directors (Board) has elected Salvatore (Sal) Mancuso to serve as Altria's CEO upon Billy's retirement. To facilitate a smooth transition, Billy plans to serve as a consultant to Altria upon his retirement through at least the end of 2026. Additionally, the Board elected Heather Newman to serve as Altri

    12/11/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Declares Regular Quarterly Dividend of $1.06 Per Share

    Altria Group, Inc. (NYSE:MO) today announced that our Board of Directors declared a regular quarterly dividend of $1.06 per share, payable on January 9, 2026 to shareholders of record as of December 26, 2025. The ex-dividend date is December 26, 2025. View source version on businesswire.com: https://www.businesswire.com/news/home/20251210780457/en/ Altria Client Services Investor Relations 804-484-8222 Altria Client Services Media Relations 804-484-8897 www.altria.com/contact-us/media

    12/10/25 1:30:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Reports 2025 Third-Quarter and Nine-Months Results; Announces Expanded Share Repurchase Program; Narrows 2025 Full-Year Earnings Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2025 third-quarter and nine-months business results, announces the expansion of our existing share repurchase program and narrows our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "Altria continued to build significant momentum in the third quarter with exciting progress across our businesses," said Billy Gifford, Altria's Chief Executive Officer. "Our core tobacco businesses remained resilient; we advanced our smoke-free portfolio; and we opened new pathways for long-term adjacent growth in international modern oral and U.S. non-nicotine innovation." "We also continue to demonstrate our commitment to returning valu

    10/30/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Davis Robert Matthews bought $48,599 worth of shares (1,200 units at $40.50), increasing direct ownership by 16% to 8,473 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    11/8/23 3:08:44 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Clarke Ian L.T. bought $44,625 worth of shares (1,100 units at $40.57), increasing direct ownership by 18% to 7,145 units (SEC Form 4)

    4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

    11/8/23 3:03:21 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/13/24 4:58:48 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/13/23 2:49:28 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

    SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

    2/9/23 10:54:46 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Financials

    Live finance-specific insights

    View All

    Altria Declares Regular Quarterly Dividend of $1.06 Per Share

    Altria Group, Inc. (NYSE:MO) today announced that our Board of Directors declared a regular quarterly dividend of $1.06 per share, payable on January 9, 2026 to shareholders of record as of December 26, 2025. The ex-dividend date is December 26, 2025. View source version on businesswire.com: https://www.businesswire.com/news/home/20251210780457/en/ Altria Client Services Investor Relations 804-484-8222 Altria Client Services Media Relations 804-484-8897 www.altria.com/contact-us/media

    12/10/25 1:30:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Reports 2025 Third-Quarter and Nine-Months Results; Announces Expanded Share Repurchase Program; Narrows 2025 Full-Year Earnings Guidance

    Altria Group, Inc. (NYSE:MO) today reports our 2025 third-quarter and nine-months business results, announces the expansion of our existing share repurchase program and narrows our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "Altria continued to build significant momentum in the third quarter with exciting progress across our businesses," said Billy Gifford, Altria's Chief Executive Officer. "Our core tobacco businesses remained resilient; we advanced our smoke-free portfolio; and we opened new pathways for long-term adjacent growth in international modern oral and U.S. non-nicotine innovation." "We also continue to demonstrate our commitment to returning valu

    10/30/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Increases Quarterly Dividend to $1.06 Per Share

    Altria Group, Inc. (NYSE:MO) today announced that our Board of Directors voted to increase our regular quarterly dividend by 3.9% to $1.06 per share versus the previous rate of $1.02 per share. This increase marks the 60th dividend increase in the past 56 years. The quarterly dividend is payable on October 10, 2025 to shareholders of record as of September 15, 2025. The ex-dividend date is September 15, 2025. The new annualized dividend rate is $4.24 per share, representing a dividend yield of 6.3% based on our closing stock price of $67.58 on August 20, 2025. Today's dividend increase is consistent with our progressive dividend goal that targets mid-single digits dividend per share gro

    8/21/25 1:00:00 PM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    $MO
    Leadership Updates

    Live Leadership Updates

    View All

    Altria Group, Inc. Announces Retirement of CEO Billy Gifford and Appointment of Sal Mancuso as Successor

    Altria Group, Inc. (Altria) (NYSE:MO) announces today that Billy Gifford, Altria's Chief Executive Officer (CEO), has decided to retire, effective May 14, 2026 at the conclusion of the 2026 Annual Meeting of Shareholders (2026 Annual Meeting). Billy has had a distinguished career of over 30 years with the Altria family of companies and has served as Altria's CEO since 2020. Altria's Board of Directors (Board) has elected Salvatore (Sal) Mancuso to serve as Altria's CEO upon Billy's retirement. To facilitate a smooth transition, Billy plans to serve as a consultant to Altria upon his retirement through at least the end of 2026. Additionally, the Board elected Heather Newman to serve as Altri

    12/11/25 7:00:00 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group, Inc. Announces Retirement of Director George Muñoz from Board of Directors

    Altria Group, Inc. (Altria) (NYSE:MO) -- George Muñoz, a director of Altria since 2004, notified Altria of his decision to retire from service on our Board of Directors (Board) following the completion of his current term. Consequently, Mr. Muñoz will not stand for re-election to our Board at our 2026 Annual Meeting of Shareholders, which Altria anticipates holding on May 14, 2026. "George has made extensive and significant contributions to Altria over more than 20 years," said Kathryn McQuade, Altria's independent Chair of the Board. "We thank George for his long-standing and valuable service and wish him the very best upon his retirement." Mr. Muñoz is Chair of the Compensation and Ta

    10/9/25 8:35:00 AM ET
    $LAUR
    $MO
    Other Consumer Services
    Real Estate
    Medicinal Chemicals and Botanical Products
    Health Care

    Altria Group, Inc. Announces Retirement of Director Jacinto J. Hernandez From Board of Directors

    Jacinto J. Hernandez, a director of Altria Group, Inc. ("Altria"), retired from service on our Board of Directors effective February 23, 2024. Mr. Hernandez will continue to serve Altria as a strategic advisor under a 5-year advisory services agreement. "We thank Jacinto for his service on our Board," said Kathryn McQuade, Altria's independent Board Chair. "Our Board benefited from his industry experience and financial expertise." "I joined Altria's Board because I am inspired by Altria's Vision to responsibly lead the transition of adult smokers to a smoke-free future," said Mr. Hernandez. "I am pleased that this agreement will allow me to focus my attention on helping Altria pursue it

    2/26/24 4:30:00 PM ET
    $ARIS
    $MO
    $PXD
    Oilfield Services/Equipment
    Energy
    Medicinal Chemicals and Botanical Products
    Health Care